Should Patients With Melanoma Receive Targeted Therapy or Immunotherapy First?

Chapter 2

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, discusses the current debate about whether patients with melanoma should receive targeted therapy or immunotherapy first.

Chapter 1

Immunotherapy: A Decade of Improvements in Melanoma

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, describes how immunotherapy transformed the treatment of metastatic melanoma. Doctors in the 1990’s relied on chemotherapy, which was ineffective in this setting, in the last decade, however, oncologists have “unlocked” T cells, which transformed clinical care for these patients.

Chapter 3

Melanoma: Checkpoints in the Pipeline

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, describes new receptors and checkpoints that oncologists may be able to manipulate to aid in the treatment of metastatic melanoma.

Chapter 4

Targeting Therapy for Melanoma Subtypes

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, describes how different varieties of melanoma are caused by different oncogenes, including BRAF, NRAS, and KIT.

Chapter 5

Melanoma: Targetable Genes in the Pipeline

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, discusses oncogenes present in melanoma that may be targetable with novel agents in development.

Chapter 6

Clinical Trials in Melanoma

In this video, Dr Gary Schwartz, chief of the hematology/oncology service at New York-Presbyterian/Columbia University Medical Center in New York, New York, discusses the benefits of clinical trials for patients with metastatic melanoma.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs